Search for: "Eli Lilly & Co." Results 41 - 60 of 1,009
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
Trees for the Forest: Claiming Endpoints of a Range and Written Description
30 Nov 2021, 9:36 am by Dennis Crouch
Eli Lilly & Co., 598 F.3d 1336 (Fed. [read post]
Patently-O - http://patentlyo.com/patent
CAFC affirms PTAB in INDIVIOR UK LIMITED v. DR. REDDY'S LABORATORIES S.A.
27 Nov 2021, 2:12 pm by Lawrence B. Ebert
Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. [read post]
IPBiz - http://ipbiz.blogspot.com/
Obviousness Of Method Claim Requires Expectation of Success for Recited Purpose
17 Sep 2021, 12:18 pm by Courtenay C. Brinckerhoff
In Eli Lilly and Co. v. [read post]
PharmaPatents - https://www.foley.com/en/insights/blogs/pharmapatents
Age Discrimination in Sales Alleged in Federal Employment Lawsuit
12 Sep 2021, 10:37 am by Nassiri Law
Eli Lilly and Co say they were qualified and did well in their interviews, but were ultimately passed over for sales positions by younger, less qualified workers. [read post]
Orange County Employment Lawyers Blog - http://www.orangecountyemploymentlawyersblog.com/
Kite wins appeal and reversal of jury verdict
26 Aug 2021, 12:55 pm by Lawrence B. Ebert
Co., 896 F.3d 1357, 1361 (Fed. [read post]
IPBiz - http://ipbiz.blogspot.com/
Teva Pharmaceuticals Int'l GmbH v. Eli Lilly & Co., Eli Lilly & Co. v. Teva Pharmaceuticals Int'l GmbH, and Teva Pharmaceuticals Int'l GmbH v. Eli Lilly & Co. (Fed. Cir. 2021)
18 Aug 2021, 9:31 pm by Patent Docs
Noonan -- The Federal Circuit issued three decisions on Monday relating to Eli Lilly & Co's. challenge in separate inter partes review proceedings on obviousness grounds of nine patents licensed by Teva Pharmaceuticals Int'l, with disparate results. [read post]
Patent Docs - http://www.patentdocs.org/
Lilly loses challenges to Teva patents; interpreting preambles
16 Aug 2021, 2:44 pm by Lawrence B. Ebert
Eli Lilly & Co. v. [read post]
IPBiz - http://ipbiz.blogspot.com/
Teva loses at CAFC on US patents 9,340,614 (“’614 patent”), 9,266,951 (“’951 patent”), and 9,890,210 (“’210 patent”)
16 Aug 2021, 2:37 pm by Lawrence B. Ebert
Eli Lilly & Co. v. [read post]
IPBiz - http://ipbiz.blogspot.com/
Fifth Circuit Declines to Take a Side in the FCA Circuit Split on DOJ’s Dismissal Authority Pursuant to 31 U.S.C. § 3730(c)(2)(A)
26 Jul 2021, 1:23 pm by Brian Tully McLaughlin, Michael Shaheen, Lyndsay Gorton and Alexandra Barbee-Garrett
Eli Lilly & Co. [read post]
Government Contracts Legal Forum - http://www.governmentcontractslegalforum.com/
CAFC discusses written description in Flashcontrol, LLC
16 Jul 2021, 12:53 pm by Lawrence B. Ebert
Eli Lilly & Co., 598 F.3d 1336, 1352 (Fed. [read post]
IPBiz - http://ipbiz.blogspot.com/
Written Description in the Life Sciences: The Devil is in the Details
8 Jun 2021, 9:15 am by Sharon Roberg-Perez
Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. [read post]
IPWatchdog.com | Patent Copyright Trademark - http://www.ipwatchdog.com
Book Review: The Protection of Intellectual Property Rights Under International Investment Law
20 Apr 2021, 5:10 am by Anastasiia Kyrylenko
Uruguay [commented by Simon Klopschinski for The IPKat here], Eli Lilly v. [read post]
IPKat - http://ipkitten.blogspot.com/
Lead Pigment Verdicts Vacated Upon Improper Expansion of State Tort Law
17 Apr 2021, 4:31 pm by Sean Wajert
Eli Lilly Co., 116 Wis.2d 166, 342 N.W.2d 37 (1984) a DES case. [read post]
Mass Tort Defense - http://www.masstortdefense.com/
Pfizer and BioNTech Claim Immunity from COVID-19 Vaccine Testing IP Claim
16 Apr 2021, 12:48 pm by Jessica R. Corpuz
”  Citing Eli Lilly & Co. v. [read post]
IP Law Blog - http://www.theiplawblog.com/
[UPDATE] IPKat/LSE Joint Event: The CJEU's billion-dollar questions - who gets a SEP licence and when should an injunction be granted?
15 Apr 2021, 9:57 am by Annsley Merelle Ward
Samsung, Eli Lilly v. [read post]
IPKat - http://ipkitten.blogspot.com/
IPKat/LSE Joint Event: The CJEU's billion-dollar questions - who gets a SEP licence and when should an injunction be granted?
1 Apr 2021, 5:14 am by Annsley Merelle Ward
Samsung, Eli Lilly v. [read post]
IPKat - http://ipkitten.blogspot.com/
Possible Ramifications of Recent FDA Alert About Xeljanz Heart Problems and Xeljanz-related Cancers
23 Mar 2021, 1:35 pm by Tom Lamb
Specifically, besides Xeljanz there are two other JAK inhibitors approved by the FDA: Olumiant (baricitinib) from Eli Lilly & Co.; and, Rinvoq (upadacitinib) from AbbVie. [read post]
Drug Injury Watch - http://www.drug-injury.com/druginjurycom/
U.S. Federal Circuit Continues To Pressure BioPharma For More When It Comes To Functional Claims
19 Feb 2021, 2:28 am by Charlotte Jacobsen (Ropes & Gray LLP), Filko Prugo (Ropes & Gray LLP) and Dinis Cheian (Ropes & Gray LLP)
This second appeal followed with Bristol Myers Squibb Co., Pfizer Inc., and Eli Lilly and Company, among others, filing dueling amicus briefs. [read post]
Kluwer Patent Blog - http://patentblog.kluweriplaw.com/
Xeljanz Has A New Drug Safety Issue, We Just Don't Know How Significant It Is, Yet
17 Feb 2021, 1:40 pm by Tom Lamb
Besides Xeljanz, there are two other JAK inhibitors approved by the FDA: Olumiant (baricitinib) from Eli Lilly & Co.; and, Rinvoq (upadacitinib) from AbbVie. [read post]
Drug Injury Watch - http://www.drug-injury.com/druginjurycom/
Illumina illuminated in the twilight of Birss J’s Patents Court career – part I
29 Jan 2021, 7:20 am by Nicolas Round (Bristows)
  The second part of the summary will consider the “co-location” validity challenge made against a fourth patent. [read post]
Kluwer Patent Blog - http://patentblog.kluweriplaw.com/